Table 3. Hematologic Toxicity During the... | American Society of Hematology

Table 3.

Hematologic Toxicity During the First Cycle of Chemotherapy in 35 Patients Who Received Filgrastim Plus Placebo or PEG-rHuMGDF 0.3 μg/kg Through 5.0 μg/kg

	Placebo + Filgrastim (n = 10)	PEG-rHuMGDF* + Filgrastim (n = 25)	P
Days to baseline platelet count	22 (18-28)	17 (9-28)	.014^3-151
Days of ANC <1.0 × 10⁹/L	2 (0-10)	3 (0-8)	.66^3-152
Days to baseline ANC count	12 (11-18)	12 (11-27)	.96^3-151
Patients with febrile neutropenia (n)	1	4	1.0ρ
Maximum change in hematocrit	−8% (−17% to −4%)	−7% (−14% to 0%)	0.12^3-152

	Placebo + Filgrastim (n = 10)	PEG-rHuMGDF* + Filgrastim (n = 25)	P
Days to baseline platelet count	22 (18-28)	17 (9-28)	.014^3-151
Days of ANC <1.0 × 10⁹/L	2 (0-10)	3 (0-8)	.66^3-152
Days to baseline ANC count	12 (11-18)	12 (11-27)	.96^3-151
Patients with febrile neutropenia (n)	1	4	1.0ρ
Maximum change in hematocrit	−8% (−17% to −4%)	−7% (−14% to 0%)	0.12^3-152

Median (range) where given. Febrile neutropenia = temperature >38.2°C and ANC <1.0 × 10⁹/L.

F3-150

Recovery for all patients administered doses of PEG-rHuMGDF of 0.3, 1.0, 3.0, or 5.0 μg/kg.

F3-151

Log-rank test.

F3-152

Rank sum test.

ρ Fisher's Exact test.

View Large

This Feature Is Available To Subscribers Only